Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NASDAQ:NBIX) on Monday, setting a price target of $145, which is approximately 51.74% above the present share price of $95.56.
Olson expects Neurocrine to post earnings per share (EPS) of -$0.62 for the fourth quarter of 2020.
The current consensus among 15 TipRanks analysts is for a Moderate Buy rating of shares in Neurocrine, with an average price target of $123.23.
The analysts price targets range from a high of $145 to a low of $90.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $258.5 million and a net profit of $74.2 million. The company's market cap is $8.89 billion.
According to TipRanks.com, Oppenheimer analyst Jay Olson is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.8% and a 39.01% success rate.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.